OCUMENSION-B(01477.HK): First Patient Enrolled in Phase III Clinical Trial of OT-802 (Pilocarpine Hydrochloride Eye Drops)

NewTimeSpace News: Ocumension Therapeutics (01477.HK) released a voluntary announcement on May 28, 2026, stating that the first patient has been enrolled in the Phase III clinical trial of OT-802 (Pilocarpine Hydrochloride Eye Drops).
OT-802 is an innovative product independently developed by the company for the treatment of presbyopia. Preclinical studies demonstrate that it delivers rapid efficacy and boasts a high safety level. The product applies the proprietary dual-chamber liquid formulation technology used for OT-101 (0.01% Atropine Sulfate Eye Drops), which effectively addresses product stability issues. The Group holds the exclusive patent for this technology. The application for the Phase III clinical trial of OT-802 was accepted by the Center for Drug Evaluation of the National Medical Products Administration in June 2025.
The successful enrollment of the first patient marks a major milestone in the clinical development of OT-802 in China, and reflects the Group’s commitment to advancing therapies for presbyopia.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.